Semax is a synthetic heptapeptide with the reference sequence MEHFPGP, supplied as a lyophilised research material for controlled studies of melanocortin-fragment signalling, neurotrophin expression, transcriptomic responses and functional connectivity.
Research material only
This material is not supplied as a medicine, treatment, supplement or consumer product. It is not for human or veterinary use, consumption or administration, and is not intended to diagnose, treat, cure or prevent any disease.
Compound overview
CompoundSemax
Reference sequenceMEHFPGP
Research classSynthetic heptapeptide
Alternative designationACTH(4–7)-Pro-Gly-Pro
Reference molecular massApproximately 813.9 Da
FormLyophilised material
Research context
Semax is a seven-amino-acid peptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its N-terminal MEHF motif corresponds to residues 4–7 of adrenocorticotropic hormone, followed by a C-terminal Pro-Gly-Pro extension.
Published experimental work has examined Semax in rat neurotrophin-expression and transcriptomic models, protein-expression studies following experimental cerebral ischaemia, and small exploratory functional-connectivity studies. These sources provide compound-level context only and do not establish the identity, performance or suitability of the material supplied on this page.
Batch documentation
Independent analytical documentation is published where available for specific batches and variations. A result indicator appears only when a published record is available. Match the vial size and batch identifier to the corresponding report before relying on any result.
Supply and laboratory handling
- Supplied in the vial size selected above.
- Provided as a lyophilised material for laboratory research.
- Use calibrated equipment and an independently validated protocol appropriate to the intended study.
- Record the product designation, vial size, batch identifier and preparation conditions in the laboratory record.
Frequently asked questions
What is Semax?
Semax is a synthetic seven-amino-acid peptide with the reference sequence Met-Glu-His-Phe-Pro-Gly-Pro, abbreviated MEHFPGP.
How is Semax related to ACTH?
The N-terminal MEHF sequence corresponds to residues 4–7 of adrenocorticotropic hormone. Semax adds a Pro-Gly-Pro extension and is therefore commonly designated ACTH(4–7)-Pro-Gly-Pro.
What research is linked on this page?
The Research tab links to compound-identification data and published studies concerning neurotrophin expression, transcriptomic and protein-expression responses, and functional connectivity. These sources provide scientific context and are not product-performance claims.
Which vial sizes are available?
Current vial sizes and availability are shown in the size selector above. This information updates with the product variations rather than being fixed in the description.
Are published laboratory results available?
Where a published batch record exists, a result indicator appears beside the applicable variation and the corresponding documentation is available on the lab-results page. No indicator means that no product-specific published result is currently displayed for that variation.
How should Semax be stored?
Protect sealed lyophilised vials from light, moisture and repeated temperature changes. After reconstitution, store the reconstituted solution refrigerated at 2–8°C and follow a validated laboratory protocol for handling and use.
Information reviewed 29 August 2026.
Batch-specific analytical documentation
Independent analytical results are published for selected Havoc Labs products, vial sizes and batches. The result attached to one variation must not be treated as evidence for a different size or batch.
- Result available: a published report is available for the marked variation.
- Test pending: a sample has been submitted, but no completed result is being claimed.
- No indicator: no product-specific result is currently displayed for that variation.
Check the identifiers
Always match the compound, vial size and batch reference on the product to the corresponding laboratory record. Where the laboratory provides an independent verification facility, use it to confirm the report.
Browse published lab results →
Storage and stability
Storage requirements can vary by compound, physical form, intended storage duration and batch. Follow the lot-specific documentation and your laboratory’s validated procedure wherever these are available.
| Form |
Suggested storage |
Important note |
| Sealed lyophilised material |
Keep in a cool, dry place, refrigerated at 2–8°C or frozen, as appropriate for the compound and intended storage period. |
Keep sealed, dry and protected from direct light. Follow compound- and batch-specific documentation and avoid repeated temperature cycling. |
| Reconstituted solution |
Refrigerate at 2–8°C unless the applicable laboratory protocol specifies otherwise. |
Stability depends on the preparation conditions, solvent, concentration, container and handling. No universal storage period is claimed. |
No universal shelf-life is claimed
Do not assume a fixed expiry or prepared-solution storage period unless it is supported by relevant stability data or batch documentation. Where a lot-specific document gives different instructions, that document takes precedence.
Published research
The sources below concern Semax under the materials and experimental conditions used by their authors. They provide compound-level scientific context and do not establish the identity, purity, performance or suitability of any supplied batch.
- PubChem. ACTH(4–7), Pro-Gly-Pro- — Compound Summary, CID 9811102. Reference sequence, formula, structure and computed molecular mass for Semax. View on PubChem ↗
- Agapova TY et al. Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH 4–10. Neuroscience Letters, 2007. Rat-brain research examining short-term NGF and BDNF gene-expression responses. View on PubMed ↗
- Lebedeva IS et al. Effects of Semax on the Default Mode Network of the Brain. Bulletin of Experimental Biology and Medicine, 2018. Exploratory resting-state fMRI research in 24 healthy participants. View on PubMed ↗
- Panikratova YaR et al. Functional Connectomic Approach to Studying Selank and Semax Effects. Doklady Biological Sciences, 2020. Exploratory resting-state functional-connectivity research in 52 healthy participants. View on PubMed ↗
- Sudarkina OYu et al. Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4–7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion. International Journal of Molecular Sciences, 2021. Rat-model research examining transcript and protein-expression responses after experimental ischaemia-reperfusion. View on PubMed ↗
Experimental literature is not product or clinical evidence
The cited literature includes animal-model and small exploratory human imaging studies. It does not establish safety or efficacy for any use and does not establish the identity, purity or performance of the material supplied on this page. Confirm the reference sequence and batch identifier against the applicable analytical documentation.
